Goldman Sachs Highlights Improving Occupancy and Cash Flow Visibility at Healthpeak Properties Inc. (DOC)

Healthpeak Properties Inc. (NYSE:DOC) is included among 10 Best Monthly Dividend Stocks to Buy Now.

Goldman Sachs Highlights Improving Occupancy and Cash Flow Visibility at Healthpeak Properties Inc. (DOC)

On January 9, Goldman Sachs started coverage of Healthpeak Properties Inc. (NYSE:DOC) with a Neutral rating and a $17 price target. In a research note, the analyst said channel checks and modeling point to solid upside in senior housing occupancy, RevPOR, and margins. Over time, those gains may run into limits tied to vacancy levels, affordability, and new supply. At the same time, Goldman sees improving cash flow visibility from NNN structures and better-defined opportunities across senior housing REIT investments.

The firm also noted how much Healthpeak’s portfolio has changed since 2019. The biggest shift came with the merger with Physicians Realty Trust, which closed on March 1, 2024. That deal effectively doubled the size of Healthpeak’s outpatient medical portfolio and reshaped the company’s overall mix.

A few days earlier, on January 7, Healthpeak announced plans to form and take public Janus Living, Inc., a new REIT focused entirely on senior housing. Healthpeak plans to contribute its 34-community, 10,422-unit senior housing portfolio to Janus Living and will act as its external manager. After the IPO, Healthpeak expects to keep a controlling interest, with public shareholders owning the rest.

Healthpeak Properties Inc. (NYSE:DOC) operates as a fully integrated healthcare REIT. The company acquires, develops, owns, leases, and manages healthcare real estate across the United States, with a focus on building long-term value across its platform.

While we acknowledge the potential of DOC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

While we acknowledge the potential of DOC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DOC and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 13 Companies that Just Started Paying Dividends and Dividend Growth Stocks: 25 Aristocrats

Disclosure: None.